Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Conditions: KRAS Gene Mutation; Metastatic Malignant Neoplasm in the Brain; Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7 Interventions: Drug: Methotrexate; Other: Pharmacokinetic Study; Drug: Regorafenib Sponsor: Stanford University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Methotrexate | Neurology | Non-Small Cell Lung Cancer | Study